WO2009083544A3 - Pdgf fusion proteins incorporated into fibrin foams - Google Patents

Pdgf fusion proteins incorporated into fibrin foams Download PDF

Info

Publication number
WO2009083544A3
WO2009083544A3 PCT/EP2008/068185 EP2008068185W WO2009083544A3 WO 2009083544 A3 WO2009083544 A3 WO 2009083544A3 EP 2008068185 W EP2008068185 W EP 2008068185W WO 2009083544 A3 WO2009083544 A3 WO 2009083544A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
fusion proteins
fibrin
foams
proteins incorporated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/068185
Other languages
French (fr)
Other versions
WO2009083544A2 (en
Inventor
Gaëlle CHARIER
Manuela MÜLLER-MAISSEN
Anna Jen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuros Biosurgery AG
Original Assignee
Kuros Biosurgery AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kuros Biosurgery AG filed Critical Kuros Biosurgery AG
Priority to EP08866549A priority Critical patent/EP2227263A2/en
Priority to JP2010540118A priority patent/JP2012512812A/en
Priority to CA2710798A priority patent/CA2710798A1/en
Priority to US12/342,420 priority patent/US8226942B2/en
Publication of WO2009083544A2 publication Critical patent/WO2009083544A2/en
Publication of WO2009083544A3 publication Critical patent/WO2009083544A3/en
Anticipated expiration legal-status Critical
Priority to US13/555,991 priority patent/US20130183279A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Compositions for wound healing, use of the compositions, and kits and methods of using thereof are described herein. In a preferred aspect, the compositions of the present invention are suitable for use in a method for forming a fibrin matrix orfoam that can be applied or injected at the site of need. In another preferred aspect, the compositions of the present invention are also suitable for use in methods for forming enhanced controlled delivery fibrin matrices that can be administered as gels or foams.
PCT/EP2008/068185 2007-12-28 2008-12-22 Pdgf fusion proteins incorporated into fibrin foams Ceased WO2009083544A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08866549A EP2227263A2 (en) 2007-12-28 2008-12-22 Pdgf fusion proteins incorporated into fibrin foams
JP2010540118A JP2012512812A (en) 2007-12-28 2008-12-22 PDGF fusion protein incorporated into fibrin foam
CA2710798A CA2710798A1 (en) 2007-12-28 2008-12-22 Pdgf fusion proteins incorporated into fibrin foams
US12/342,420 US8226942B2 (en) 2007-12-28 2008-12-23 PDGF fusion proteins incorporated into fibrin foams
US13/555,991 US20130183279A1 (en) 2007-12-28 2012-07-23 Fibrin Formulations for Wound Healing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1740907P 2007-12-28 2007-12-28
US61/017409 2007-12-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/342,420 Continuation US8226942B2 (en) 2007-12-28 2008-12-23 PDGF fusion proteins incorporated into fibrin foams

Publications (2)

Publication Number Publication Date
WO2009083544A2 WO2009083544A2 (en) 2009-07-09
WO2009083544A3 true WO2009083544A3 (en) 2010-06-10

Family

ID=40485556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/068185 Ceased WO2009083544A2 (en) 2007-12-28 2008-12-22 Pdgf fusion proteins incorporated into fibrin foams

Country Status (5)

Country Link
US (1) US8226942B2 (en)
EP (1) EP2227263A2 (en)
JP (1) JP2012512812A (en)
CA (1) CA2710798A1 (en)
WO (1) WO2009083544A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8998866B2 (en) 2010-07-02 2015-04-07 Smith & Nephew Plc Provision of wound filler

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009067711A2 (en) 2007-11-21 2009-05-28 T.J. Smith & Nephew, Limited Suction device and dressing
CN104382691B (en) 2007-11-21 2018-08-31 史密夫及内修公开有限公司 wound dressing
GB0722820D0 (en) 2007-11-21 2008-01-02 Smith & Nephew Vacuum assisted wound dressing
GB0723875D0 (en) 2007-12-06 2008-01-16 Smith & Nephew Wound management
US11253399B2 (en) 2007-12-06 2022-02-22 Smith & Nephew Plc Wound filling apparatuses and methods
US20130096518A1 (en) 2007-12-06 2013-04-18 Smith & Nephew Plc Wound filling apparatuses and methods
GB0803564D0 (en) 2008-02-27 2008-04-02 Smith & Nephew Fluid collection
US8512740B2 (en) 2008-03-26 2013-08-20 Baxter International Inc. Fibrin foam and process for making
US8753670B2 (en) 2008-03-26 2014-06-17 Baxter International Inc. Fibrin foam and process
GB0902816D0 (en) 2009-02-19 2009-04-08 Smith & Nephew Fluid communication path
US20130202564A1 (en) * 2010-04-09 2013-08-08 University Of Southern California Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration
US9061095B2 (en) 2010-04-27 2015-06-23 Smith & Nephew Plc Wound dressing and method of use
CN107033596A (en) 2010-11-25 2017-08-11 史密夫及内修公开有限公司 Composition I-II and products thereof and purposes
GB201020005D0 (en) 2010-11-25 2011-01-12 Smith & Nephew Composition 1-1
US20150159066A1 (en) 2011-11-25 2015-06-11 Smith & Nephew Plc Composition, apparatus, kit and method and uses thereof
US20160120706A1 (en) 2013-03-15 2016-05-05 Smith & Nephew Plc Wound dressing sealant and use thereof
EP2968647B1 (en) 2013-03-15 2022-06-29 Smith & Nephew plc Wound dressing sealant and use thereof
CN107427601B (en) * 2015-03-27 2021-08-31 3M创新有限公司 Fibrin compositions, methods and articles for use in wounds
US10501715B1 (en) 2015-09-11 2019-12-10 Mark H. Widick System for the formation of fibrin foam
CN109789091A (en) * 2016-09-14 2019-05-21 奥姆里克斯生物药品有限公司 Stable pharmaceutical foam
US10940233B2 (en) 2016-10-05 2021-03-09 3M Innovative Properties Company Fibrinogen composition, method and wound articles
EP3522942B1 (en) 2016-10-05 2023-12-27 3M Innovative Properties Company Fibrin composition comprising carrier material, method and wound articles
EP3536353A1 (en) * 2018-03-09 2019-09-11 Kuros Biosurgery AG Method and kits for producing a fibrin matrix

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187232A1 (en) * 1998-08-27 2003-10-02 Eidgenossische Technische Hochschule Zurich Universitat Zurich Growth factor modified protein matrices for tissue engineering
US20050180957A1 (en) * 2004-01-16 2005-08-18 Scharp David W. Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
US7189410B1 (en) * 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
SE8200751L (en) * 1982-02-09 1983-08-10 Olle Larm PROCEDURE FOR COVALENT COUPLING FOR MANUFACTURE OF CONJUGATE AND REQUIRED PRODUCTS
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
AU2258788A (en) 1987-07-07 1989-01-30 Cytrx Biopool Ltd. Fibrin-binding compound and method
US5504001A (en) * 1987-11-25 1996-04-02 Zymogenetics, Inc. Hybrid plasminogen activator
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
DE68929472T2 (en) 1988-04-08 2004-05-13 Stryker Corp., Kalamazoo Biosynthetic bone-forming proteins and bone-forming devices containing them
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5137819A (en) * 1988-07-08 1992-08-11 University Of British Columbia Cellulose binding fusion proteins for immobilization and purification of polypeptides
AU630643B2 (en) 1988-11-09 1992-11-05 Protein Polymers Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
WO1990009783A1 (en) 1989-02-22 1990-09-07 Massachusetts Institute Of Technology Delivery system for controlled release of bioactive factors
US5171670A (en) * 1989-05-12 1992-12-15 The General Hospital Corporation Recombinant dna method for production of parathyroid hormone
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
US5169764A (en) 1990-08-08 1992-12-08 Regeneron Pharmaceuticals, Inc. Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras
US6559119B1 (en) * 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
EP0564502B1 (en) 1990-11-27 2002-01-30 The American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
SE9101853D0 (en) 1991-06-17 1991-06-17 Jonas Wadstroem IMPROVED TISSUE ASHESIVE
US5270300A (en) 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
SE470006B (en) * 1991-09-26 1993-10-25 Corline Systems Ab New conjugate, its preparation and use, and substrates prepared with the conjugate
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5814603A (en) * 1992-06-12 1998-09-29 Affymax Technologies N.V. Compounds with PTH activity
US5589452A (en) * 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
CN1091315A (en) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 Fibrin sealant compositions and methods of use thereof
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
NO934477L (en) 1992-12-09 1994-06-10 Ortho Pharma Corp PEG hydrazone and PEG oxime-binding reagents and protein derivatives thereof
DE69433920T2 (en) 1993-03-12 2005-06-02 American National Red Cross SUPPLEMENTED COMPRESSION AGENTS FOR TISSUE, METHODS FOR THEIR PRODUCTION AND THEIR USE
US5428014A (en) 1993-08-13 1995-06-27 Zymogenetics, Inc. Transglutaminase cross-linkable polypeptides and methods relating thereto
US5773577A (en) * 1994-03-03 1998-06-30 Protein Polymer Technologies Products comprising substrates capable of enzymatic cross-linking
US5859874A (en) * 1994-05-09 1999-01-12 Globalstar L.P. Multipath communication system optimizer
CA2155762C (en) 1994-08-23 2000-04-25 Haruya Sato Protein modification method
AU717906B2 (en) 1994-12-07 2000-04-06 American National Red Cross, The Supplemented and unsupplemented tissue sealants, methods of their production and use
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5693341A (en) * 1995-03-16 1997-12-02 Collagen Corporation Affinity bound collagen matrices for the delivery of biologically active agents
US5561982A (en) * 1995-05-02 1996-10-08 Universal Vortex, Inc. Method for energy separation and utilization in a vortex tube which operates with pressure not exceeding atmospheric pressure
JP2000500019A (en) 1995-11-16 2000-01-11 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for producing peptide via streptavidin fusion protein
US7026292B1 (en) * 1995-12-12 2006-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
PT876165E (en) * 1995-12-18 2006-10-31 Angiotech Biomaterials Corp COMPOSITIONS OF RETICULATED POLYMERS AND PROCESSES FOR THEIR USE
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US5874308A (en) * 1996-01-16 1999-02-23 University Of British Columbia Compositions and methods for modulating cell proliferation using growth factor-polysaccharide binding fusion proteins
US5877153A (en) * 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
EP0950665A4 (en) 1996-09-26 2004-05-06 Ajinomoto Kk Modified physiologically active proteins and medicinal compositions containing the same
AU6245898A (en) 1997-01-21 1998-08-07 Genetics Institute Inc. Injectable formulations for treatment of osteoporotic bone
CA2307954C (en) * 1997-04-03 2010-07-13 California Institute Of Technology Enzyme-medicated modification of fibrin for tissue engineering
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
CN1269805A (en) 1997-07-14 2000-10-11 博尔德生物技术公司 Derivatives of growth hormone and related proteins
GB9722604D0 (en) 1997-10-28 1997-12-24 Cancer Res Campaign Tech Heparin-binding growth factor derivatives
WO1999031137A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Crystalline teriparatide
US5958874A (en) 1998-02-18 1999-09-28 The Research Foundation Of State University Of New York Recombinant fibronectin-based extracellular matrix for wound healing
NZ509238A (en) 1998-07-27 2003-07-25 Emisphere Tech Inc Pulmonary delivery of active agents the carrier containing acylated or sulfonated amino acids
DZ2873A1 (en) 1998-08-19 2003-12-15 Lilly Co Eli Method for increasing bone hardness and stiffness.
US6894022B1 (en) * 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7241730B2 (en) * 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
US6663870B2 (en) * 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
CA2359318C (en) 1999-02-01 2009-06-30 Universitat Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
EP1151116A1 (en) 1999-02-19 2001-11-07 Terumo Kabushiki Kaisha Collagen-binding physiologically active polypeptide
MXPA01010692A (en) * 1999-04-22 2004-09-06 Univ Zuerich Modified protein matrices.
WO2000064481A1 (en) 1999-04-22 2000-11-02 Eidgenössische Technische Hochschule (ETH) Controlled release of growth factors from heparin containing matrices
US6468543B1 (en) * 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
KR100345214B1 (en) 1999-08-17 2002-07-25 이강춘 The nasal transmucosal delivery of peptides conjugated with biocompatible polymers
US6303138B1 (en) * 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
US6608293B2 (en) * 1999-12-17 2003-08-19 Agilent Technologies Inc. Method of and apparatus for testing a photosensor
US6811776B2 (en) * 2000-12-27 2004-11-02 The Regents Of The University Of Michigan Process for ex vivo formation of mammalian bone and uses thereof
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
DE60042795D1 (en) 2000-05-01 2009-10-01 Eth Zuerich MATRICES FROM MODIFIED GROWTH FACTORS FOR TISSUE CONSTRUCTION
DE20010297U1 (en) 2000-06-08 2000-08-31 ETH Zürich, Zürich Enzyme-mediated modification of fibrin for tissue manipulation: fibrin formulations with peptides
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins
CA2681952A1 (en) * 2001-04-25 2002-10-31 Eidgenoessische Technische Hochschule Zurich Drug delivery matrices to enhance wound healing
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
EP1477496A4 (en) * 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd PEG BINDING PTH OR PEG BINDING PTH DERIVATIVE
WO2003084481A2 (en) 2002-04-01 2003-10-16 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Biological affinity based delivery systems
US20050010297A1 (en) * 2003-05-08 2005-01-13 Kuros Biosurgery Ag Balloon technologies for tissue repair
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
EP1828244A2 (en) * 2004-12-22 2007-09-05 Kuros Biosurgery AG Michael-type addition reaction functionalised peg hydrogels with factor xiiia incorporated biofactors
BRPI0606409A2 (en) * 2005-01-06 2009-06-23 Kuros Biosurgery Ag supplemented matrices for bone fracture repair
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
US20060168718A1 (en) * 2005-02-01 2006-08-03 Frederick Watson Urinal enclosure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189410B1 (en) * 1990-11-27 2007-03-13 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US20030187232A1 (en) * 1998-08-27 2003-10-02 Eidgenossische Technische Hochschule Zurich Universitat Zurich Growth factor modified protein matrices for tissue engineering
US20050180957A1 (en) * 2004-01-16 2005-08-18 Scharp David W. Method of using fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8998866B2 (en) 2010-07-02 2015-04-07 Smith & Nephew Plc Provision of wound filler

Also Published As

Publication number Publication date
EP2227263A2 (en) 2010-09-15
US20090169539A1 (en) 2009-07-02
WO2009083544A2 (en) 2009-07-09
CA2710798A1 (en) 2009-07-09
JP2012512812A (en) 2012-06-07
US8226942B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
WO2008073448A3 (en) Pharmaceutical formulations and methods for making the same
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2020028677A3 (en) Programmable designer therapeutic fusogenic secreted gectosome vesicles for macromolecule delivery and genome modification
WO2008073628A3 (en) Compositions and methods for arthrodetic procedures
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2013060769A3 (en) Hemostatic compositions
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007064885A3 (en) Oral care compositions, methods, devices and systems
IL195788A (en) Ophthalmic formulation of vascular endothelial growth factor antagonist, a method of producing the same and syringe suitable for intravitreal administration comprising the same
WO2009021209A3 (en) Bi-layered bone-like scaffolds
WO2009081408A3 (en) Pulverized fibrin clots and pharmaceutical compositions containing them
WO2007089864A3 (en) Sutures and fibrosing agents
WO2008060622A3 (en) Improved methods and compositions for wound healing
WO2008065388A3 (en) Biogel
WO2009131730A3 (en) IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2007144644A3 (en) Extracellular matrix composition
WO2007059202A3 (en) Pyrazolyl urea derivatives useful in the treatment of cancer
WO2008077094A3 (en) Methods for promoting neovascularization
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
WO2008042973A3 (en) Lipid containing formulations
WO2009038673A3 (en) Thieno-and furo-pyrimidine modulators of the histamine h4 receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08866549

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008866549

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010540118

Country of ref document: JP

Ref document number: 2710798

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/007216

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE